Exclusive Summary

• - The 2.5 mg S-amlodipine positions as “low-dose equivalence with potentially less edema,” addressing global needs for elderly, naïve, and combination-therapy initiation.
• - With ~1.28 billion people with hypertension and >120 million with ischemic heart disease worldwide, DHP-CCBs are first-line in major guidelines, sustaining steady demand.
• - Originator patents have expired (EU ~2004–2010; US 2007) and most S-amlodipine IP has lapsed or is design-aroundable, enabling multi-country fast registration and distribution.
• - Versus the originator, generics typically deliver 80–95% price cuts; common ex-factory for 2.5 mg is ~USD 0.02–0.06/tablet, fitting OOP markets and tenders.
• - With CTD dossier, Zone IVb stability, and recognized GMP/(if available) WHO-PQ, access and tender success improve markedly; Vietnam requires direct local partnering (no China-agency route).